JP2023538594A5 - - Google Patents

Info

Publication number
JP2023538594A5
JP2023538594A5 JP2023512073A JP2023512073A JP2023538594A5 JP 2023538594 A5 JP2023538594 A5 JP 2023538594A5 JP 2023512073 A JP2023512073 A JP 2023512073A JP 2023512073 A JP2023512073 A JP 2023512073A JP 2023538594 A5 JP2023538594 A5 JP 2023538594A5
Authority
JP
Japan
Prior art keywords
compound
hydrogen
formula
alkyl
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538594A (ja
JP7851034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046778 external-priority patent/WO2022040473A1/en
Publication of JP2023538594A publication Critical patent/JP2023538594A/ja
Publication of JP2023538594A5 publication Critical patent/JP2023538594A5/ja
Application granted granted Critical
Publication of JP7851034B2 publication Critical patent/JP7851034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512073A 2020-08-19 2021-08-19 選択されたプリンホスホルアミデートの立体選択的製造 Active JP7851034B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063067726P 2020-08-19 2020-08-19
US63/067,726 2020-08-19
US202063074302P 2020-09-03 2020-09-03
US63/074,302 2020-09-03
US202063094759P 2020-10-21 2020-10-21
US63/094,759 2020-10-21
US202063129306P 2020-12-22 2020-12-22
US63/129,306 2020-12-22
PCT/US2021/046778 WO2022040473A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Publications (3)

Publication Number Publication Date
JP2023538594A JP2023538594A (ja) 2023-09-08
JP2023538594A5 true JP2023538594A5 (https=) 2024-08-27
JP7851034B2 JP7851034B2 (ja) 2026-04-24

Family

ID=80323295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512073A Active JP7851034B2 (ja) 2020-08-19 2021-08-19 選択されたプリンホスホルアミデートの立体選択的製造

Country Status (10)

Country Link
US (1) US20230331751A1 (https=)
EP (1) EP4200309A4 (https=)
JP (1) JP7851034B2 (https=)
KR (1) KR20230053640A (https=)
CN (1) CN115884977A (https=)
AU (1) AU2021327241A1 (https=)
CA (1) CA3173661A1 (https=)
MX (1) MX2023002064A (https=)
TW (1) TW202214260A (https=)
WO (1) WO2022040473A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN121628124B (zh) * 2026-02-05 2026-04-10 山东鲁源化工科技有限公司 一种高热稳定性聚磷酸酯阻燃剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870169A1 (en) * 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
CA3182565A1 (en) * 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Similar Documents

Publication Publication Date Title
JP2023538594A5 (https=)
CN113248508B (zh) N-保护的杂环类化合物、其制备方法及其用于制备c-核苷衍生物的方法
ES2641761T3 (es) Procedimientos para preparar inhibidores JAK y compuestos intermedios relacionados
CN101541818B (zh) 4'-叠氮基胞苷衍生物的制备方法
JP2024503855A (ja) アミノピリミジン系fak阻害剤化合物を合成する方法
JP7851034B2 (ja) 選択されたプリンホスホルアミデートの立体選択的製造
ES2738211T3 (es) Procedimiento mejorado de preparación de profármacos a base de duocarmicina
WO2018104953A1 (en) Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
CN104039771B (zh) 包括c(7)‑oh和c(13)‑oh甲硅烷基化或仅c(7)‑oh甲硅烷基化的用于制备卡巴他赛的方法
CN106083807B (zh) 4-氨基-5-联苯-4-基-2-羟甲基-2-甲基-戊酸化合物及其制备方法
EP3411359B1 (en) Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
EP1904489B1 (en) Process for the synthesis of triazoles
KR20100102107A (ko) β-뉴클레오시드의 새로운 합성 방법
TWI887245B (zh) 用於產生二氮雜螺內醯胺化合物之方法及中間物
EP3515915B1 (en) Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
JP2023517735A (ja) オキシム中間体及び関連化合物を介した3’nヌクレオシドの合成
CN102924454B (zh) 恩替卡韦的合成方法
ES2314449T3 (es) Derivados de peptidil cetona heterociclicos y procedimiento de preparacion.
EP3891160A1 (en) Process for the preparation of a cyclic dinucleotide
WO2017134607A1 (en) A process for the preparation of phosphatidylinositol 3-kinase inhibitor
CN119161348A (zh) 一种依鲁替尼及其合成方法
JP4181233B2 (ja) ピロリジン−2,4−ジオン誘導体の製法
HK40120549A (en) Processes and intermediates for producing diazaspiro lactam compounds
WO2024135609A1 (ja) 核酸合成用リンカー、及び担体、並びにそれらの製造方法
WO2017134548A1 (en) Process for the preparation of ledipasvir and intermediates thereof